NCT00809133 - Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Neoplasms

Interventions

DRUG

Paclitaxel

Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.

DRUG

Carboplatin

AUC6 given on day 1 of 21 day cycle

DRUG

BIBW 2992

Escalating dose cohorts

DRUG

Paclitaxel

Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.

DRUG

BIBW2992

MTD dose of part A

DRUG

Paclitaxel

175mg/m2 given on Day 1 of 21 Day cycle

DRUG

Carboplatin

AUC6 given on day 1 of 21 day cycle

DRUG

Bevacizumab

Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle

DRUG

BIBW 2992

Escalating dose cohorts

DRUG

BIBW 2992

Escalating dose cohorts

Trial Locations (2)

1200.12.4402 Boehringer Ingelheim Investigational Site, London

1200.12.4401 Boehringer Ingelheim Investigational Site, Sutton